Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action

Journal of Molecular and Cellular Cardiology

Volumn 28, Issue 7, 1996, Pages 1523-1529

  Waltenberger, Johannes ^a   Mayr, Ulrike ^a   Frank, Hedwig ^a   Hombach, Vinzenz ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Angiogenesis factor; Endothelium; Gene expression regulation; Growth factor; Myocardial ischemia; Receptors; Vascular

Indexed keywords

ANTITRYPANOSOMAL AGENT; SURAMIN; TYROSINE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL CULTURE; CHEMOTAXIS; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HEART MUSCLE ISCHEMIA; MITOGENICITY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SWINE;

ANIMALIA; SUS SCROFA;

EID: 0030198685     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0142     Document Type: Article

References (30)

1. ARLT W, REINCKE M, SIEKMANN L, WINKELMANN W, ALLOLIO B, 1994. Suramin in adrenocortical cancer -limited efficacy and serious toxicity. Clin Endocrinol 41: 299-307.
2. ASADA Y, TSUNEYOSHI A, MARUTSUKA K, SUMIYOSHI A, 1994. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovosc Res 28: 1166-1169.
3. BANAI S, JAKLITSCH MT, SHOU M, LAZAROUS DF, SCHEINOWITZ M, BIRO S, EPSTEIN SE, UNGER EF, 1994. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189.
4. BANAI S, SHWEIKI D, PINSON A, CHANDRA M, LAZAROVICI G, KESHET E, 1994. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28: 1176-1179.
5. BERNARDINI N, GIANNESSI F, BIANCHI F, DOLFI A, LUPETTI M, CITTI L, DANESI R, DEL TM, 1993. Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation. Br J Cancer 67: 1209-1216.
6. BETSHOLTZ C, JOHNSSON A, HELDIN C-H, WESTERMARK B, 1986. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA 83: 6440-6444.
7. BRADDOCK PS, HU D-E, FAN T-PD, STRATFORD IJ, HARRIS AL, BICKNELL R, 1993. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 69: 890-898.
8. CLAUSS M, GERLACH M, GERLACH H, BRETT J, WANG F, FAMILLETTI P, PAN Y-C, OLANDER JV, CONNOLLY DT, STERN D, 1990. Vascular permeability factor: a tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172: 1535-1545.
9. CONNOLLY DT, HEUVELMAN DM, NELSON R, OLANDER JV, EPPLEY BL, DELFINO JJ, SIEGEL NR, LEIMGRUBER RM, FEDER J, 1989. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470-1478.
10. COOPER JA, HUNTER T, 1981. Changes in protein phosphorylation in rous sarcoma virus-transformed chicken embryo cells. Mol Cell Biol 1: 165-178.
11. DANESI R, DEL BS, SOLDANI P, CAMPAGNI A, LA RR, MYERS CE, PAPARELLI A, DEL TM, 1993. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68: 932-938.
12. DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT, 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
13. GAGLIARDI A, HADD H, COLLINS DC, 1992. Inhibition of angiogenesis by suramin. Cancer Res 52: 5073-5075.
14. HOSANG M, 1985. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29: 265-273.
15. KEHINDE EO, TERRY TR, MISTRY N, HORSBURGH T, SANDHU DP, BELL PR, 1995. UK studies on suramin therapy in hormone-resistant prostate-cancer. Cancer Surv 23: 217-229.
16. LARSEN AK, 1993. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 32: 96-98.
17. LEUNG DW, CACHIANES G, KUANG W-J, GOEDDEL DV, FERRARA N, 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
18. MIDDAUGH CR, MACH H, BURKE CJ, VOLKIN DB, DABORA JM, TSAI PK, BRUNER MW, RYAN JA, MARFIA KE, 1992. Nature of the interaction of growth factors with suramin. Biochemistry 31: 9016-9024.
19. MOTZER RJ, NANUS DM, O'MOORE P, SCHER HI, BAJORIN DF, REUTER V, TONG WP, IVERSEN J, LOUISON C, ALBINO AP, BOSL GJ, 1992. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52: 5775-5779.
20. O'BRIAN ER, GARVIN MR, DEV R, STEWART DK, HINOHARA T, SIMPSON JB, SCHWARTZ SM, 1994. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 145: 883-894.
21. PEARLMAN JD, HIBBERD MG, CHUANG ML, HARADA K, LOPEZ JJ, GLADSTONE SR, FRIEDMAN M, SELLKE FW, SIMONS M, 1995. Magnetic resonance mapping demonstrates benefits of VEGF-induced angiogenesis. Nature Med 1: 1085-1089.
22. RAVERA F, MIGLIETTA L, PIRANI P, FERRINI S, FAVONI RE, 1993. Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events. Eur J Cancer 29A: 225-230.
23. SCHAPER W, SHARMA HS, QUINKLER W, MARKERT T, WÜNSCH M, SCHAPER J, 1990. Molecular biologic concepts of coronary anastomoses. J Am Coll Cardiol 15: 513-518.
24. SENGER DR, GALLI SJ, DVORAK AM, PERRUZZI CA, HARVEY VS, DVORAK HF, 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
25. STEIN CA, 1993. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239-2248.
26. TAKANO S, GATELY S, NEVILLE ME, HERBLIN WF, GROSS JL, ENGELHARD H, PERRICONE M, EIDSVOOG K, BREM S, 1994. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660.
27. TERMAN BI, DOUGHER-VERMAZEN M, CARRION ME, DIMITROV D, ARMELLINO DC, GOSPODAROWICZ D, BÖHLEN P, 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-586.
28. VOOGD TE, VANSTERKENBURG EL, WILTING J, JANSSEN LH, 1993. Recent research on the biological activity of suramin. Pharmacol Rev 45: 177-203.
29. WALTENBERGER J, CLAESSON-WELSH L, SIEGBAHN A, SHIBUYA M, HELDIN C-H, 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
30. YANAGISAWA-MIWA A, UCHIDA Y, NAKAMURA F, TOMARU T, KIDO H, KAMIJO T, SUGIMOTO T, KAJI K, UTSUYAMA M, KURASHIMA C, ITO H, 1992. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401-1403.